Yusuf Kemal Arslan, Ilyas Sayar, Mehmet Gurbuzel, Aliseydi Bozkurt, Soner Baydeniz

Quantification of cell-free DNA from bladder cancer patients after long-term storage and its use in determining CCAT2, HRAS, and RET polymorphism: A pilot study

Aim: The level of free DNA is used as a cancer biomarker due to having several advantages related to lower cost, easy applicability, and rapid results compared to invasive methods. Materials and Methods: This study investigated whether or not free DNA functions as intended when stored. The free DNA isolated for this purpose was kept at –80 degrees for four years. Then, the level of free DNA was measured in patients with bladder cancer by both photometric and fluorometric methods, and it was investigated whether this biomarker was effective in determining Single Nucleotide Polymorphisms (SNP). The gene names and the reference numbers of the locations where polymorphism was expected were as follows: CCAT2 (rs6983267), HRAS (rs12628), and RET (rs1799939). Results: According to the results, having the T allele at rs12628 increases the risk of disease by 2.6 times (OR: 2.60; 95% CI: 1.10– 6.10) and having the G allele at rs1799939 increases the risk of disease 2.7 times (OR: 2.70; 95% CI: 1.12–6.69). Conclusions: The general findings showed that fluorometric measurements were more advantageous when considering the sensitivity of free DNA measurements. It was also concluded that, if treated rapidly and conserved in appropriate laboratory conditions, free DNA can be effectively used in SNP studies. This study provides important data to demonstrate the quality of free DNA.

PDF

___

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. I J Cancer 2010;127:2893-917.
2. Jankovic S, Vladan R. Risk factors for bladder cancer. Tumori 2007;93:4-12.
3. Schmitz-Dräger BJ, Droller M, Lokeshwar VB, et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int 2015;94:1-24.
4. Sorenson GD, Pribish DM, Valone FH, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Prevention Biomarkers Prev 1994;3:67–71.
5. Vasioukhin V, Anker P, Maurice P, et al. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. B J Haematol 1994;86:774-9.
6. Chen XQ, Stroun M, Magnenat JL, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996;2:1033-5.
7. Nawroz H, Koch W, Anker P, et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996;2:1035-7.
8. Volik S, Alcaide M, Morin RD, Collins C. Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging Technologies. Mol Cancer Res 2016;14:898-908.
9. Brisuda A, Pazourkova E, Soukup V, et al. Urinary cellfree DNA quantification as non-invasive biomarker in patients with bladder cancer. Urol Int 2006;96:25-31.
10. Deligezer U, Eralp Y, Akisik EE, et al. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med 2008;46:311-7.
11. Zancan M, Galdi F, Di Tonno F, et al. Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. Int J Biol Markers 2009;24:147-55.
12. Ponti G, Maccaferri M, Manfredini M, et al. The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients. Clin Chim Acta 2018;479:14-9.
13. Yolcu M, Dogan A, Kurtoglu N, et al. New indicator of cellular ischemia in coronary slow-flow phenomenon: Cell-free DNA. Turk Kardiyol Dern Ars 2020;48:558– 65.
14. Li J, Zhuang C, Liu Y, et al. shRNA targeting long non-coding RNA CCAT2 controlled by tetracyclineinducible system inhibits progression of bladder cancer cells. Oncotarget 2016;7:28989-97.
15. Zeng J, Du T, Song Y, et al. Knockdown of Long Noncoding RNA CCAT2 Inhibits Cellular Proliferation, Invasion, and Epithelial-Mesenchymal Transition in Glioma Cells. Oncol Res 2017;25:913-21.
16. Park SL, Chang SC, Cai L, et al. Associations between variants of the 8q24 chromosome and nine smokingrelated cancer sites. Cancer Epidemiol Biomarkers Prev 2008;17:3193-202.
17. Wokołorczyk D, Gliniewicz B, Sikorski A, et al. A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res 2008;68:9982-6.
18. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49;4682-9
19. Macaluso M, Russo G, Cinti C, Bazan V, Gebbia N, Russo A. Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol 2002;192:125-30.
20. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012;72:2457- 67.
21. Sanyal S, Festa F, Sakano S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004;25:729-34.
22. Pandith AA, Shah ZA, Khan NP, et al. HRAS T81C polymorphism modulates risk of urinary bladder cancer and predicts advanced tumors in ethnic Kashmiri population. Urol Oncol 2013;31:487-92.
23. Johne A, Roots I, Brockmöller J. A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. Cancer Epidemiol Biomarkers Prev 2003;12:68-70.
24. Pandey A, Duan H, Di-Fiore PP, Dixit VM. The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10. J Biol Chem 1995;270:21461-3.
25. Manié S, Santoro M, Fusco A, et al. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet 2001;17:580-9.
26. Elisei R, Cosci B, Romei C, et al. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 2004;89:3579-84.
27. Baumgartner-Parzer SM, Lang R, Wagner L, et al. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?. J Clin Endocrinol Metab 2005;90:6232-6.
28. Robledo M, Gil L, Pollán M, et al. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 2003;63:1814-7.
29. Sawai H, Okada Y, Kazanjian K, et al. The G691S RET polymorphism increases glial cell line–derived neurotrophic factor–induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 2005;65:11536-44.
30. Wohllk NG, Soto EC, Bravo MA, Becker PC. G691S, L769L and S836S ret proto-oncogene polymorphisms are not associated with higher risk to sporadic medullary thyroid carcinoma in Chilean patients. Rev Med Chil 2005;133:397-402.